Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator | Apply Online

Opportunity Summary:

The Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator grant opportunity (Funding Opportunity Number EP PMC 16 001) is a federal effort to rebuild the early-stage antibacterial drug pipeline in response to the growing threat of antimicrobial resistance. The premise behind the program is that too few promising antimicrobial candidates are moving forward from early proof-of-concept work into the preclinical stage, where they become more attractive for later private investment and eventual clinical development. This opportunity is aligned with the 2014 US National Strategy for Combating Antimicrobial Resistant Bacteria, which called for new ways to stimulate innovation and reduce the scientific and financial barriers that keep early antimicrobial programs from advancing.

The program is structured as a biopharmaceutical accelerator focused only on antibacterial products, not antivirals or antifungals. Its goal is to push candidate antibacterial products through key research and development milestones spanning proof-of-concept through preclinical development. In practical terms, the accelerator is meant to help mature early programs by funding the experiments, studies, and development activities that de-risk a candidate and make it more competitive for follow-on funding and clinical-stage partnerships. The expectation is that products that "graduate" from the accelerator will be in a stronger position to attract additional R and D investment and proceed into clinical development.

A defining feature of this accelerator model is that it is non-equity and provides non-dilutive support. Rather than taking ownership stakes in participating companies or requiring founders to give up control, the model is designed to keep product developers in full ownership and operational control of their organizations. This is intended to make participation attractive to startups and other product developers who might otherwise avoid accelerators or investors that require equity, while still giving them access to resources that can materially advance their programs.

The award mechanism is a cooperative agreement, which generally implies substantial federal involvement during the period of performance compared with a more hands-off grant. The opportunity sits in the Science and Technology and other Research and Development category (CFDA 93.360) and is administered under HHS-OS-ASPR, reflecting the involvement of the Office of the Assistant Secretary for Preparedness and Response. The Biomedical Advanced Research and Development Authority (BARDA) is positioned to provide direct funding, while the National Institute of Allergy and Infectious Diseases (NIAID) contributes in-kind support to strengthen the accelerator's technical capabilities. The in-kind components explicitly include preclinical services and technical expertise, which can be critical for small teams that lack access to specialized testing, animal models, regulatory-quality study design, or translational development know-how.

The intended recipient under the cooperative agreement is an organization that will operate the accelerator and manage a portfolio of investments into early-stage antimicrobial product candidates. In other words, the awardee is not simply advancing one product; it is expected to function as a portfolio manager and accelerator operator that selects, supports, and oversees multiple antibacterial development efforts. This portfolio approach is meant to spread risk across multiple candidates while systematically increasing the number of programs that reach a more investment-ready stage.

Eligibility for this funding is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including those without 501(c)(3) status, other than higher education institutions), for-profit organizations other than small businesses, small businesses, and additional entity types as described in the full announcement. The government set an award ceiling of $30,000,000 and anticipated making two awards, signaling an intent to fund a small number of accelerator operators at a substantial scale rather than distributing many smaller grants.

Key timeline details in the announcement show it was created and posted on February 17, 2016, with an application closing date of April 15, 2016. Overall, the opportunity is aimed at fixing a specific bottleneck in antibacterial innovation by pairing BARDA funding with NIAID technical support inside a non-dilutive, non-equity accelerator framework, so that more early antibacterial candidates can survive the difficult jump from proof-of-concept to robust preclinical readiness.

Browse more opportunities from the same agency: HHS-OS-ASPR

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: Antarctic Artists and Writers Program

Previous opportunity: Provider Education and Public Awareness about Primary Immunodeficiency Disease

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for EP PMC 16 001

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (EP PMC 16 001) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "EP PMC 16 001", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.